8 results on '"Barry,Houreratou"'
Search Results
2. Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
- Author
-
Rouamba, Toussaint, Ouédraogo, Esperance, Barry, Houreratou, Yaméogo, Nobila Valentin, Sondo, Apoline, Boly, Rainatou, Zoungrana, Jacques, Ouédraogo, Abdoul Risgou, Tahita, Marc Christian, Poda, Armel, Diendéré, Arnaud Eric, Ouedraogo, Abdoul-Salam, Valea, Innocent, Traoré, Isidore, Tarnagda, Zekiba, Drabo, Maxime K, and Tinto, Halidou
- Published
- 2022
- Full Text
- View/download PDF
3. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
- Author
-
Barry, Houreratou, primary, Lhomme, Edouard, additional, Surénaud, Mathieu, additional, Nouctara, Moumini, additional, Robinson, Cynthia, additional, Bockstal, Viki, additional, Valea, Innocent, additional, Somda, Serge, additional, Tinto, Halidou, additional, Meda, Nicolas, additional, Greenwood, Brian, additional, Thiébaut, Rodolphe, additional, and Lacabaratz, Christine, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study
- Author
-
Puri, Adeep, primary, Pollard, Andrew J., additional, Schmidt-Mutter, Catherine, additional, Lainé, Fabrice, additional, PrayGod, George, additional, Kibuuka, Hannah, additional, Barry, Houreratou, additional, Nicolas, Jean-François, additional, Lelièvre, Jean-Daniel, additional, Sirima, Sodiomon Bienvenu, additional, Kamala, Beatrice, additional, Manno, Daniela, additional, Watson-Jones, Deborah, additional, Gaddah, Auguste, additional, Keshinro, Babajide, additional, Luhn, Kerstin, additional, Robinson, Cynthia, additional, and Douoguih, Macaya, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
- Author
-
Anywaine, Zacchaeus, Barry, Houreratou, Anzala, Omu, Mutua, Gaudensia, Sirima, Sodiomon B., Eholie, Serge, Kibuuka, Hannah, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen C., Cohen, Kristen W., Shukarev, Georgi, Katwere, Michael, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Thiébaut, Rodolphe, and Douoguih, Macaya
- Subjects
Immunogenetics -- Methods ,Ebola virus infections -- Risk factors -- Diagnosis -- Care and treatment ,Immune response -- Analysis ,Ebola virus -- Identification and classification -- Control -- Prevention ,Biological sciences - Abstract
Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in adolescents and children in Africa. Methods and findings In this multicentre, randomised, observer-blind, placebo-controlled Phase II study, 131 adolescents (12 to 17 years old) and 132 children (4 to 11 years old) were enrolled from Eastern and Western Africa and randomised 5:1 to receive study vaccines or placebo. Vaccine groups received intramuscular injections of Ad26.ZEBOV (5 x 10.sup.10 viral particles) and MVA-BN-Filo (1 x 10.sup.8 infectious units) 28 or 56 days apart; placebo recipients received saline. Primary outcomes were safety and tolerability. Solicited adverse events (AEs) were recorded until 7 days after each vaccination and serious AEs (SAEs) throughout the study. Secondary and exploratory outcomes were humoral immune responses (binding and neutralising Ebola virus [EBOV] glycoprotein [GP]-specific antibodies), up to 1 year after the first dose. Enrolment began on February 26, 2016, and the date of last participant last visit was November 28, 2018. Of the 263 participants enrolled, 217 (109 adolescents, 108 children) received the 2-dose regimen, and 43 (20 adolescents, 23 children) received 2 placebo doses. Median age was 14.0 (range 11 to 17) and 7.0 (range 4 to 11) years for adolescents and children, respectively. Fifty-four percent of the adolescents and 51% of the children were male. All participants were Africans, and, although there was a slight male preponderance overall, the groups were well balanced. No vaccine-related SAEs were reported; solicited AEs were mostly mild/moderate. Twenty-one days post-MVA-BN-Filo vaccination, binding antibody responses against EBOV GP were observed in 100% of vaccinees (106 adolescents, 104 children). Geometric mean concentrations tended to be higher after the 56-day interval (adolescents 13,532 ELISA units [EU]/mL, children 17,388 EU/mL) than the 28-day interval (adolescents 6,993 EU/mL, children 8,007 EU/mL). Humoral responses persisted at least up to Day 365. A limitation of the study is that the follow-up period was limited to 365 days for the majority of the participants, and so it was not possible to determine whether immune responses persisted beyond this time period. Additionally, formal statistical comparisons were not preplanned but were only performed post hoc. Conclusions The heterologous 2-dose vaccination was well tolerated in African adolescents and children with no vaccine-related SAEs. All vaccinees displayed anti-EBOV GP antibodies after the 2-dose regimen, with higher responses in the 56-day interval groups. The frequency of pyrexia after vaccine or placebo was higher in children than in adolescents. These data supported the prophylactic indication against EBOV disease in a paediatric population, as licenced in the EU. Trial registration ClinicalTrials.gov NCT02564523., Author(s): Zacchaeus Anywaine 1, Houreratou Barry 2, Omu Anzala 3, Gaudensia Mutua 3, Sodiomon B. Sirima 4, Serge Eholie 5, Hannah Kibuuka 6, Christine Bétard 7, Laura Richert 7,8, Christine [...]
- Published
- 2022
- Full Text
- View/download PDF
6. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
- Author
-
Barry, Houreratou, Mutua, Gaudensia, Kibuuka, Hannah, Anywaine, Zacchaeus, Sirima, Sodiomon B., Meda, Nicolas, Anzala, Omu, Eholie, Serge, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen, Cohen, Kristen W., Shukarev, Georgi, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Douoguih, Macaya, and Thiébaut, Rodolphe
- Subjects
HIV patients -- Patient outcomes ,Biological sciences - Abstract
Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2 sites each in Burkina Faso, Cote d'Ivoire, and Uganda. Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end of the study. The primary endpoint was safety, and the secondary endpoint was immunogenicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were measured at baseline and at predefined time points throughout the study. The first participant was enrolled on 9 November 2015, and the date of last participant's last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs were observed among the participants. The most frequent solicited AEs were injection-site pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confidence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and 7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day interval groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817), respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vaccination after 1 year induced an anamnestic response. Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. Conclusions Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children [greater than or equal to]1 year of age. Trial registration ClinicalTrials.gov NCT02564523, Author(s): Houreratou Barry 1, Gaudensia Mutua 2, Hannah Kibuuka 3, Zacchaeus Anywaine 4, Sodiomon B. Sirima 5, Nicolas Meda 1, Omu Anzala 2, Serge Eholie 6, Christine Bétard 7, Laura [...]
- Published
- 2021
- Full Text
- View/download PDF
7. Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
- Author
-
Rouamba, Toussaint, primary, Barry, Houreratou, additional, Ouédraogo, Espérance, additional, Tahita, Marc Christian, additional, Yaméogo, Nobila Valentin, additional, Poda, Armel, additional, Diendéré, Eric Arnaud, additional, Ouedraogo, Abdoul-Salam, additional, Valea, Innocent, additional, Koné, Amariane M, additional, Thiombiano, Cherileila, additional, Traoré, Isidore, additional, Tarnagda, Zekiba, additional, Sawadogo, Serge Aimé, additional, Gansané, Zakaria, additional, Kambiré, Yibar, additional, Sanou, Idrissa, additional, Barro-Traoré, Fatou, additional, Drabo, Maxime K, additional, and Tinto, Halidou, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
- Author
-
Rouamba,Toussaint, Barry,Houreratou, Ouédraogo,Espérance, Tahita,Marc Christian, Yaméogo,Nobila Valentin, Poda,Armel, Diendéré,Eric Arnaud, Ouedraogo,Abdoul-Salam, Valea,Innocent, Koné,Amariane M, Thiombiano,Cherileila, Traoré,Isidore, Tarnagda,Zekiba, Sawadogo,Serge Aimé, Gansané,Zakaria, Kambiré,Yibar, Sanou,Idrissa, Barro-Traoré,Fatou, Drabo,Maxime K, Tinto,Halidou, Rouamba,Toussaint, Barry,Houreratou, Ouédraogo,Espérance, Tahita,Marc Christian, Yaméogo,Nobila Valentin, Poda,Armel, Diendéré,Eric Arnaud, Ouedraogo,Abdoul-Salam, Valea,Innocent, Koné,Amariane M, Thiombiano,Cherileila, Traoré,Isidore, Tarnagda,Zekiba, Sawadogo,Serge Aimé, Gansané,Zakaria, Kambiré,Yibar, Sanou,Idrissa, Barro-Traoré,Fatou, Drabo,Maxime K, and Tinto,Halidou
- Abstract
Toussaint Rouamba,1,* Houreratou Barry,2,* Esperance Ouédraogo,1 Marc Christian Tahita,1 Nobila Valentin Yaméogo,3 Armel Poda,4 Arnaud Eric Diendéré,5 Abdoul-Salam Ouedraogo,4 Innocent Valea,1 Amariane M Koné,2 Cherileila Thiombiano,2 Isidore Traoré,2 Zekiba Tarnagda,1 Serge A Sawadogo,6 Zakaria Gansané,7 Yibar Kambiré,8 Idrissa Sanou,8 Fatou Barro-Traoré,8 Maxime K Drabo,1 Halidou Tinto1 On behalf of the CHLORAZ Study Group1Institut de Recherche en Sciences de la Santé (CNRST-IRSS), Nanoro, Burkina Faso; 2Institut National de Santé Publique, Centre Muraz, Bobo-Dioulasso, Burkina Faso; 3Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso; 4Centre Hospitalier Universitaire Sourou Sanon, Bobo-Dioulasso, Burkina Faso; 5Centre Hospitalier Universitaire de Bogodogo, Ouagadougou, Burkina Faso; 6Centre PrïmO Nelson Mandela (Promotion de la Recherche et de lâInnovation en Immunologie Médicale de Ouagadougou), Ouagadougou, Burkina Faso; 7Clinical Monitoring in Africa-Clinical Research Organization, Ouagadougou, Burkina Faso; 8Centre Hospitalier Universitaire de Tengandogo, Ouagadougou, Burkina Faso*These authors contributed equally to this workCorrespondence: Toussaint RouambaInstitut de Recherche en Sciences de la Santé (CNRST-IRSS), 528, Avenue Kumda-Yoore, BP 218 Ouagadougou CMS 11, Ouagadougou, Nanoro, Burkina FasoTel +226 666 532 04Email rouambatoussaint@gmail.comIntroduction: Though chloroquine derivatives are used in the treatment of coronavirus disease 2019 (COVID-19) in many countries worldwide, doubts remain about the safety and efficacy of these drugs, especially in African communities where published data are scarce.Methods: We conducted an observational prospective cohort study from April 24 to September 03, 2020, in Burkina Faso to assess (as primary outcome) the clinical, biological, and cardiac (electrocardiographic) safety of chloroquine or hydroxychloroquine plus azithromycin administered to
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.